****THE FIRST ORDER****

[RZB]

PROPHET IN DA HOUSE!!!!!!!

[©PROPHETABLE]

GAXCQ gotta good feeling about this one!!!

[RZB]

GAXCQ READY FOR BIG THINGS

[Mean Weimaraner]

$GAXCQ record high volume today

[RZB]

GAXCQ MULTI BAGGER IN THE MAKING

[RiverNorth]

+115% !!!!!

[Mean Weimaraner]

$LEAS flexing boys

[Mean Weimaraner]

$GAXCQ

[UndergroundTrader]

MCAP!!!!!!!!!!!!! http://www.otcmarkets.com/stock/MCAP/news

[$Pistol Pete$]

$PMCB January 25th 2016: Austrianova expands its business area







Austrianova announced today that, having completed the set up of its new GMP facility, it is now offering clients a GMP cell banking (Master Cell Bank and Working Cell Bank) as well as a “Fill and Finish” service for cell therapy products, in addition to its encapsulation services and technology. Austrianova is able to offer the production of Master Cell and Working Cell Banks (MCB and WCB) at the size scale required for early (phase 1 and 2) stage clinical trials at highly competitive prices using its state of the art isolator based production facility, assuring that the highest quality standards are adhered to. The company can also fill bulk cell product into syringes or vials in its GMP facility. This new cell banking and filling service is called GMP4Cells. MCB’s and WCB’s are required for all cell therapy products such as stem cell therapies as well as biologics produced from cells such as vaccines, antibodies, recombinant proteins etc. Similarly, many companies, including those developing stem cell lines and products, are seeking high quality economic fill and finish for relative small lots.

“We see this as a natural add-on to our already established Cell-in-a-Box® cell encapsulation technology for which we have recently set up a GMP manufacturing facility in Thailand. This kind of MCB and WCB production as well as “Fill and Finish” services for cells are, however, stand alone services. Although these services are generally available to all customers, they should allow start up companies and academic based cell products, vaccines etc to enter clinical trials in a quality assured manner but at lower cost that other, more conventional, cell banking companies offer” stated Walter H. Gunzburg, Chairman and CTO of Austrianova.

“In addition to our state of the art facility, Austrianova offers services that comply with major international regulatory agencies using a customized German/Swiss based quality assurance system. Our team has many years experience with regulatory agencies around the world and has taken cell therapies into clinical trials” said Brian Salmons, CEO.


http://austrianova.com/news/ewExternalFiles/PR%20GMP4Cells%20.pdf

[RiverNorth]

Hearing grumblings on $VAPR negotiations

[ForReal]

My IFCR opinion synopsis....

You have to realize what this is all about and what the business plan is here.

First is getting rid of the debt. That basically has been toxic convertible notes. Many of the so called "Fluff" PR's were to aid note holders in selling converted shares. But, also to help share holders by trying to aid debt holders to sell at as high a SP as possible, to stay within the stricture of the A/S and to keep the share structure as small as possible.

At the same time, the CEO is trying to add value to the company via acquisitions that add to the bottom line financially. This is kind of tricky, simply because it is a rather difficult thing to try and convince someone that it is in their best interests to join forces with a debt laden company whose shares sell for 10 thousands of a penny. The only way to do that is to lay out a viable business plan to assure them that shares of IFCR will not always trade at those prices.

While all this is going on, the CEO is trying to get straight with the SEC as economically as possible, to limit additional debt burden of the company. The consequence of that is, you are not going to get Deloitte & Touche or Ernst & Young. So, you are going to have some delays and the road to getting this done is going to be a little more bumpy along the way.

And finally, after all this gets done, something will have to be done with the share structure. You guessed it. There will be a reverse split. There is no other option for IFCR, if they want to reach a valuation commiserate with their financials and have serious investors become share holders and stakeholders.

Some (as most penny players do) will dump shares as soon as they hear those words, Reverse Split. But, it is my assessment that the true value of IFCR will never be accomplished until after a reverse split.

So, I see things a little differently. Currently, anyone can buy shares for .0003 & .0004. What that means is, that after a 1,000 for one reverse split, IFCR will be trading about .30 to .40 a share. It will be SEC compliant, revenue ($20 million+) and profit will have been enhanced both organically and via acquisitions, the share structure will have noticeably decreased and IFCR will probably trade at some higher level exchange.

To me, all seems in order. I may not be able to currently flip this stock, but over the long term, this is going to pay big, in my opinion. But, that is just my vision and opinion.

So, let us consider worst case scenario here.

The company issues all 5 billion shares to extinguish debt and acquire the trucking company aforementioned in previous PR's by the company. Then IFCR does a 1,000 for 1 reverse split.

The result will be: IFCR will have a 5 million share O/S.

IFCR will have approx. $30 million in revenue.
IFCR will be debt free.
Shares purchased at .0001 & .0002 will be cost valued (post split) @ .10 to .20.

A similar situation occurred with WEYL this past year. It is now trading at .52 Bid X .99 Ask.

So, I am buying all the .0001's (if I can get them) and .0002's (if I can not get .0001's). (Like I did with a comparable company earlier this year).

[RiverNorth]

What's the real deal with IFCR??

[ForReal]

GFOX getting some attention finally. 73 million in the float. Grand opening of GFOX 1st Graffiti Junktion restaurant any day now news. 10Q just filed. Moving up nicely with a nice chart. Check out GFOX website...
http://greyfoxholdings.com/

[ANTI-BAGHOLDER]

Watching ARCS next week.

[$Pistol Pete$]

$PMCB Oncomed Pharmaceuticals Stumbles, But Pharmacyte Biotech Continues to Offer Hope in War on Pancreatic Cancer

Oncomed Pharmaceuticals Inc. (NASDAQ:OMED) just reiterated today how tough pancreatic cancer is to beat. Pharmacyte Biotech Inc. (OTCMKTS:PMCB) is also tough though, and continues to move forward with the cancer community's next big leap forward in the war on pancreatic cancer.

For fans and followers of Oncomed Pharmaceuticals Inc. (NASDAQ:OMED), the new trading week is getting started on the wrong foot. Although the company is going to continue on with this particular stage of the trial, the so-called ALPINE trial of it cancer immunology drug tarextumab as a therapy for pancreatic cancer doesn't look like it's going to meet its endpoint goal.

The announcement from OMED underscores just how tough pancreatic cancer is to beat; this is hardly the first instance of a well-known (and otherwise effective therapy) failing to do much good when it comes to treating the dreaded disease. Yet, the stumble for Oncomed Pharmaceuticals also puts a small biotech firm called Pharmacyte Biotech Inc. (OTCMKTS:PMCB), as it's developing a pancreatic cancer treatment option that just might be the next, long-awaited quantum leap for this particular sliver of the oncology world.

Just for the record, in the phase 2 ALPINE trial, Oncomed Pharmaceuticals observed a distinct lack of benefit -- no progress in terms of progression-free survival or overall survival rates -- compared to a placebo. Such results contrast with trials recently performed by Pharmacyte Biotech.

Pharmacyte Biotech is the developer of a biotechnology called Cell-in-a-Box(r). In simplest terms, Cell-in-a-Box(r) is a means of encapsulating live cells -- cells grown to perform a particular function -- and implanting these pinhead-sized capsules in the body to perform a specific medical purpose. The technology has many applications, but PharmaCyte Biotech is furthest along in its development of the idea as a means of treating pancreatic cancer.

In phase 2 trials, PharmaCyte has shown that catalyzing a prodrug form of cancer-fighting therapy ifosfamide in the bloodstream physically near the cancer-ridden pancreas maximizes the effectiveness while minimizing the dosage. Ergo, this approach has proven superior to activation of the drug in the liver.

While potent, ifosfamide can also cause significant side effects when taken at doses large enough to effectively fight cancer. That's because liver-activated ifosfamide must make it all the way through the entire circulatory system before it reaches the pancreas. Most of the drug never reaches the pancreatic tumor. By activating the drug in the leg, though, the activated ifosfamide only needs to travel a few inches to reach the pancreas. The end result is an impressive degree of efficacy at only one-third the normal intravenous dosage of ifosfamide.

In a phase 1/2 trial examining the benefit of the Cell-in-a-Box(r) activation of ifosfamide versus the results gemcitabine would be able to achieve alone, the Pharmacyte approach improved the median survival timeframe from 28 to 44 weeks. Equally impressive is the fact that the number of one-year survivors increased from 18% to 36% of the study's patients.

The initial goal of Pharmacyte Biotech and its Cell-in-a-Box was as a frontline treatment, where it performed very well relative to current first-effort therapies of gemcitabine or a combination of gemcitabine and Abraxane. As the study progressed, however, the company recognized the drug ifosfamide when activated by its Cell-in-a-Box platform could effectively meet a much bigger and perhaps much more lucrative unmet need... pancreatic cancer patients for whom gemcitabine or the combination of gemcitabine and Abraxane was no longer effectively shrinking a tumor (even if it had stopped its growth).

That's about 40% of the pancreatic cancer patient population completely up for grabs, so to speak, as there is no "good" solution. Pharmacyte Biotech may be about to change that.

The next step is a redesigned phase 2 trial. The trials had to be reworked when the company recognized it would be better off aiming at a slightly different target. The new plans are taking shape right now, however, and the new phase 2 trial should begin soon. It's a reason to be excited about PMCB.

[RiverNorth]

Welcome Buddy

[BigJuan]

Yup CEO is a POS......wouldn't touch that turd or anything else that @ss has a hand in.......hope it runs for peeps but NEXT

[Mean Weimaraner]

Looking into it TY

[ForReal]

IEEC A/S 75 Million O/S 50 million Float 28 Million

Bid .0026 Ask .003 Time to make something happen there?

[Jugas]

TSOI creeping up slowly. Has had all buys on the ask this week, up 63% on low volume. Only 2 market makers on the ask below a penny. Company has been working on audited financials, so they could drop at anytime. No dilution! Look at L2, very thin!

[ANTI-BAGHOLDER]

Yes it is! CEO is a POS, but the TA is ungagged and still shows how tiny that float is.

$HNSS

[zigzagman]

That's a super low Float for a triple-zero stock!

I'll keep $HNSS on Radar

[ForReal]

GFOX up 69% on 1.7 million shares. Can you say thin brotha?

[OptimusPrime]

EVAR chart reset on a dip from a shorter. Not a smart to short such a low float.

[$Pistol Pete$]

$PMCB PharmaCyte Biotech (PMCB) is locked and loaded -- money-wise -- for a while, funded to begin the next phase of its pancreatic cancer trial. The press release was posted this morning -- PMCB pocketed $1 million via the sale of equity, bringing its cash balance up to $3 million. That should get the company pretty far down the R&D road.

As impressive as garnering a million bucks worth of funding in this environment is, I think the real story with PMCB is the chart itself.

Some of you may recall we figured the sharp, high volume selloff from December 31st was a capitulation, and the beginning of a rebound move. We still have every reason to think that. Although the stock stalled as it approached the 50-day moving average line (purple), the 20-day line (blue) has since stepped up as a floor. It even looks like the bulls are trying to use the 20-day moving average line as something of a springboard. One good push above $0.08 could ignite another round of buying.

[RiverNorth]

$ETFM: Blast This Chinese Scam Generals!

[Mean Weimaraner]

$ICNV... 0016x0017 now could be a good one..

[Jugas]

TSOI primed for a run, ask is super thin. Could run into pennies with a little volume.

[Mean Weimaraner]

$ICNV $IGPK $NESV

[OptimusPrime]

EVAR now 1.04 folks my sell order is $3.00

[OptimusPrime]

EVAR small dip to load more!

[JUST WAITING]

RSII 0017 news out going $$$$$

[ANTI-BAGHOLDER]

I don't know pal. It's sitting there at .0001x .0002. Had some nice news the past couple days and an Ungagged TA.

357 million float confirmed yesterday.


Seems like a prime breakout candidate. No?

[RiverNorth]

We ready for round two $HNSS??

[ANTI-BAGHOLDER]

$HNSS 357 million float trading at .0001x.0002!!! Ungagged TA.

Pretty crazy if you ask me.

[$Pistol Pete$]

$PMCB Oncomed Pharmaceuticals Stumbles, But Pharmacyte Biotech Continues to Offer Hope in War on Pancreatic Cancer

Oncomed Pharmaceuticals Inc. (NASDAQ:OMED) just reiterated today how tough pancreatic cancer is to beat. Pharmacyte Biotech Inc. (OTCMKTS:PMCB) is also tough though, and continues to move forward with the cancer community's next big leap forward in the war on pancreatic cancer.

For fans and followers of Oncomed Pharmaceuticals Inc. (NASDAQ:OMED), the new trading week is getting started on the wrong foot. Although the company is going to continue on with this particular stage of the trial, the so-called ALPINE trial of it cancer immunology drug tarextumab as a therapy for pancreatic cancer doesn't look like it's going to meet its endpoint goal.

The announcement from OMED underscores just how tough pancreatic cancer is to beat; this is hardly the first instance of a well-known (and otherwise effective therapy) failing to do much good when it comes to treating the dreaded disease. Yet, the stumble for Oncomed Pharmaceuticals also puts a small biotech firm called Pharmacyte Biotech Inc. (OTCMKTS:PMCB), as it's developing a pancreatic cancer treatment option that just might be the next, long-awaited quantum leap for this particular sliver of the oncology world.

Just for the record, in the phase 2 ALPINE trial, Oncomed Pharmaceuticals observed a distinct lack of benefit -- no progress in terms of progression-free survival or overall survival rates -- compared to a placebo. Such results contrast with trials recently performed by Pharmacyte Biotech.

Pharmacyte Biotech is the developer of a biotechnology called Cell-in-a-Box(r). In simplest terms, Cell-in-a-Box(r) is a means of encapsulating live cells -- cells grown to perform a particular function -- and implanting these pinhead-sized capsules in the body to perform a specific medical purpose. The technology has many applications, but PharmaCyte Biotech is furthest along in its development of the idea as a means of treating pancreatic cancer.

In phase 2 trials, PharmaCyte has shown that catalyzing a prodrug form of cancer-fighting therapy ifosfamide in the bloodstream physically near the cancer-ridden pancreas maximizes the effectiveness while minimizing the dosage. Ergo, this approach has proven superior to activation of the drug in the liver.

While potent, ifosfamide can also cause significant side effects when taken at doses large enough to effectively fight cancer. That's because liver-activated ifosfamide must make it all the way through the entire circulatory system before it reaches the pancreas. Most of the drug never reaches the pancreatic tumor. By activating the drug in the leg, though, the activated ifosfamide only needs to travel a few inches to reach the pancreas. The end result is an impressive degree of efficacy at only one-third the normal intravenous dosage of ifosfamide.

In a phase 1/2 trial examining the benefit of the Cell-in-a-Box(r) activation of ifosfamide versus the results gemcitabine would be able to achieve alone, the Pharmacyte approach improved the median survival timeframe from 28 to 44 weeks. Equally impressive is the fact that the number of one-year survivors increased from 18% to 36% of the study's patients.

The initial goal of Pharmacyte Biotech and its Cell-in-a-Box was as a frontline treatment, where it performed very well relative to current first-effort therapies of gemcitabine or a combination of gemcitabine and Abraxane. As the study progressed, however, the company recognized the drug ifosfamide when activated by its Cell-in-a-Box platform could effectively meet a much bigger and perhaps much more lucrative unmet need... pancreatic cancer patients for whom gemcitabine or the combination of gemcitabine and Abraxane was no longer effectively shrinking a tumor (even if it had stopped its growth).

That's about 40% of the pancreatic cancer patient population completely up for grabs, so to speak, as there is no "good" solution. Pharmacyte Biotech may be about to change that.

The next step is a redesigned phase 2 trial. The trials had to be reworked when the company recognized it would be better off aiming at a slightly different target. The new plans are taking shape right now, however, and the new phase 2 trial should begin soon. It's a reason to be excited about PMCB.

[Mean Weimaraner]

Dats what I been hearin ;] TY for the update

[MG-Trader]

ICNV called to TA today

115M O/S
50M FLOAT damn she might run hard.... Loading zone here

[Mean Weimaraner]

$NESV . Eyeing $IGPK $ICNV for tomorrow as well

[OptimusPrime]

Yes I've been in since 1.37 and avg down.

[ForReal]

SDLP looking really good here at $2. Paying a .25 per qtr. divi which calculates out to 50% ($1) per year.
$400 million in revenue even during this depressed oil market.

[Jugas]

TSOI up 37% on just 200k in volume, moves on air, float is tiny!

[RiverNorth]

Thank you! $RSII

[JUST WAITING]

RSII 001 going hurry $$$$$

[Mean Weimaraner]

Somethings definitely going on over there. All should keep a close eye IMO easy money

[OptimusPrime]

EVAR is this a hint? EVAR generally releases earnings in the afternoon. Monday's earnings are going to be released premarket! I think so...

[©PROPHETABLE]

NESV .0012 won't last

[Mean Weimaraner]

A good example is doximity. OVER half of physicians in the United States use doximity to connect with other doctors/hospitals. They are currently valued at over $1billion.

Nurses lounge is the same, essentially, just for nurses! Interesting thing is there is 4x as many nurses then physicians in the US.

[kairos]

MCGI looks good here ...